Fibroblast growth factor 21 as a candidate of a novel serum biomarker for mitochondrial diabetes.
Journal
Journal of diabetes investigation
ISSN: 2040-1124
Titre abrégé: J Diabetes Investig
Pays: Japan
ID NLM: 101520702
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
revised:
10
04
2023
received:
15
03
2023
accepted:
03
05
2023
medline:
23
10
2023
pubmed:
29
5
2023
entrez:
29
5
2023
Statut:
ppublish
Résumé
Serum fibroblast growth factor 21 levels in patients with mitochondrial diabetes might be much higher than in those with other diabetes types. The results of this study could lead to the establishment of a simple method for screening mitochondrial diabetes using peripheral blood serum.
Identifiants
pubmed: 37246726
doi: 10.1111/jdi.14030
pmc: PMC10360381
doi:
Substances chimiques
fibroblast growth factor 21
0
Biomarkers
0
Fibroblast Growth Factors
62031-54-3
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
1009-1010Subventions
Organisme : Japan Foundation for Applied Enzymology
Informations de copyright
© 2023 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.
Références
Diabetes Res Clin Pract. 2003 Mar;59(3):207-17
pubmed: 12590018
Diabetes Care. 2009 Aug;32(8):1542-6
pubmed: 19487637
Tohoku J Exp Med. 2016;239(2):89-94
pubmed: 27212224
Cell Metab. 2019 Dec 3;30(6):1040-1054.e7
pubmed: 31523008